[go: up one dir, main page]

WO2009007390A3 - 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors - Google Patents

2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors Download PDF

Info

Publication number
WO2009007390A3
WO2009007390A3 PCT/EP2008/058898 EP2008058898W WO2009007390A3 WO 2009007390 A3 WO2009007390 A3 WO 2009007390A3 EP 2008058898 W EP2008058898 W EP 2008058898W WO 2009007390 A3 WO2009007390 A3 WO 2009007390A3
Authority
WO
WIPO (PCT)
Prior art keywords
inylbenz
pyraz
tyrosine kinase
kinase inhibitors
receptor tyrosine
Prior art date
Application number
PCT/EP2008/058898
Other languages
French (fr)
Other versions
WO2009007390A2 (en
Inventor
Linette Rushton
Jon James Gordon Winter
Original Assignee
Astrazeneca Ab
Linette Rushton
Jon James Gordon Winter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Linette Rushton, Jon James Gordon Winter filed Critical Astrazeneca Ab
Publication of WO2009007390A2 publication Critical patent/WO2009007390A2/en
Publication of WO2009007390A3 publication Critical patent/WO2009007390A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns pyrazine derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of G1, G2, R1, m, R2, R3, n and R4 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
PCT/EP2008/058898 2007-07-09 2008-07-09 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors WO2009007390A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0713259.0A GB0713259D0 (en) 2007-07-09 2007-07-09 Pyrazine derivatives 954
GB0713259.0 2007-07-09

Publications (2)

Publication Number Publication Date
WO2009007390A2 WO2009007390A2 (en) 2009-01-15
WO2009007390A3 true WO2009007390A3 (en) 2009-03-19

Family

ID=38440612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/058898 WO2009007390A2 (en) 2007-07-09 2008-07-09 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors

Country Status (2)

Country Link
GB (1) GB0713259D0 (en)
WO (1) WO2009007390A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011123647A (en) 2008-11-10 2012-12-20 Вертекс Фармасьютикалз Инкорпорейтед COMPOUNDS USEFUL AS ATR KINASE INHIBITORS
WO2010071837A1 (en) 2008-12-19 2010-06-24 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
WO2010103388A2 (en) * 2009-03-13 2010-09-16 Bergen Teinologioverforing As Method
DE102009056886A1 (en) * 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet inhibitors for the treatment of endometriosis
JP2013529200A (en) 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
JP2013526538A (en) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
WO2011143422A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated 2 -aminopyridine derivatives useful as inhibitors of atr kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143425A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CA2803802A1 (en) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
CN103562204A (en) 2011-04-05 2014-02-05 沃泰克斯药物股份有限公司 Aminopyrazine compounds useful as inhibitors of TRA kinase
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2014517079A (en) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
CN103958507A (en) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 Compounds useful as inhibitors of ATR kinase
CN103957917A (en) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
RU2677292C2 (en) 2011-09-30 2019-01-16 Вертекс Фармасьютикалз Инкорпорейтед Processes for making compounds useful as inhibitors of atr kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071085A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
MY165215A (en) 2012-01-31 2018-03-09 Daiichi Sankyo Co Ltd Pyridone derivatives
MX358818B (en) 2012-04-05 2018-09-05 Vertex Pharma Compounds useful as inhibitors of atr kinase and combination therapies thereof.
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
ES2946360T3 (en) 2012-12-07 2023-07-17 Vertex Pharma Pyrazolo[1,5-a]pyrimidines useful as ATR kinase inhibitors for the treatment of cancer diseases
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9771333B2 (en) 2013-11-20 2017-09-26 Signalchem Lifesciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
EP3074390B1 (en) 2013-11-27 2020-07-08 SignalChem Lifesciences Corporation Aminopyridine derivatives as tam family kinase inhibitors
HRP20192183T1 (en) 2013-12-06 2020-02-21 Vertex Pharmaceuticals Inc. COMPOUND 2-AMINO-6-FLUORO-N- [5-FLUORO-PYRIDIN-3-YL] PYRAZOLO [1,5-A] PYRIMIDINE-3-CARBOXAMIDE USEFUL AS AN ATR KINASE INHIBITOR, ITS PREPARATION, VARIOUS DIFFERENT MARKED DERIVATIVES
US20170027940A1 (en) * 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
US10004732B2 (en) 2014-04-24 2018-06-26 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
MX2016013981A (en) 2014-04-24 2016-11-15 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors.
AU2014391610B2 (en) * 2014-04-24 2018-01-25 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
LT3152212T (en) 2014-06-05 2020-05-11 Vertex Pharmaceuticals Inc. Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
NZ727399A (en) 2014-06-17 2022-07-29 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
TWI690525B (en) 2014-07-07 2020-04-11 日商第一三共股份有限公司 Pyridone derivatives containing tetrahydropyranylmethyl group and use thereof
ES2764299T3 (en) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Human monoclonal antibodies against AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
KR102678021B1 (en) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Pharmaceutical composition for cancer treatment comprising an ATR inhibitor, used in combination with a DNA damaging agent
ES2896079T3 (en) 2016-02-26 2022-02-23 Ono Pharmaceutical Co Drug for cancer therapy, characterized by the administration of the combination between an Axl inhibitor and an immune checkpoint inhibitor
US20200197385A1 (en) 2017-08-23 2020-06-25 Ono Pharmaceutical Co., Ltd. Therapeutic agent for cancer containing axl inhibitor as active ingredient
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
US11306079B2 (en) 2017-12-21 2022-04-19 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
HUE057970T2 (en) 2018-03-08 2022-06-28 Incyte Corp Aminopyrazinediol compounds as PI3K-Y inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066629A2 (en) * 2002-02-06 2003-08-14 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
WO2004084813A2 (en) * 2003-03-21 2004-10-07 Smithkline Beecham Corporation Chemical compounds
WO2006063167A1 (en) * 2004-12-08 2006-06-15 Smithkline Beecham Corporation 1h-pyrrolo[2,3-b]pyridines
WO2008038010A1 (en) * 2006-09-30 2008-04-03 Vernalis (R & D) Limited Pyrazine derivatives and their use in therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066629A2 (en) * 2002-02-06 2003-08-14 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
WO2004084813A2 (en) * 2003-03-21 2004-10-07 Smithkline Beecham Corporation Chemical compounds
WO2006063167A1 (en) * 2004-12-08 2006-06-15 Smithkline Beecham Corporation 1h-pyrrolo[2,3-b]pyridines
WO2008038010A1 (en) * 2006-09-30 2008-04-03 Vernalis (R & D) Limited Pyrazine derivatives and their use in therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. J. BAMFORD ET AL.: "(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors", BIOORG. MED. CHEM. LETT., vol. 15, 9 June 2005 (2005-06-09), pages 3402 - 3406, XP002500545 *

Also Published As

Publication number Publication date
WO2009007390A2 (en) 2009-01-15
GB0713259D0 (en) 2007-08-15

Similar Documents

Publication Publication Date Title
WO2009007390A3 (en) 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
MX2009002010A (en) Heteroaryl derivatives as protein kinase inhibitors.
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009007751A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
WO2009007748A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2007049041A8 (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
SG170069A1 (en) Quinoline derivatives
MX2009011964A (en) Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof.
WO2008032072A8 (en) 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
IN2012DN02577A (en)
WO2008135791A8 (en) Imidazoquinolines with immuno-modulating properties
MY148634A (en) Pyridazinone derivatives
NO20090631L (en) Morpholine pyrimidine derivatives useful in the treatment of proliferative disorders
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
WO2010099379A8 (en) Jak kinase modulating quinazoline derivatives and methods of use thereof
MX2009010047A (en) Chemical compounds.
WO2008031556A3 (en) 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
MX2009010045A (en) Chemical compounds.
AU2009282962A8 (en) Compounds as kinase inhibitors
WO2009132774A8 (en) New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors
TW200639156A (en) New compounds
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
MX336332B (en) Kinase inhibitors, prodrug forms thereof and their use in therapy.
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08786005

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08786005

Country of ref document: EP

Kind code of ref document: A2